NeurAxis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $87.7M
- Price
- $7.08
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.70%
- Volume
- 49.0K
Quote data as of 7:03 AM ET
About
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Quick stats
Shares outstanding12.4M
Computed float8.7M
Float sourceUnknown
Cash runway (months)10.6
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001933567
Websitehttps://neuraxis.com
AI Summary
AI-generated2mo agominorneutralearningsNeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
NeurAxis announced it will release its first quarter 2026 financial results before the market open on Tuesday, May 12, 2026.
The company scheduled a conference call for the same day at 9:00 am ET to discuss the results and provide a business update.
NeurAxis is a medical technology company focused on neuromodulation therapies, including its FDA-cleared IB-Stim device.